HRT Titration: Preparing for a Dose Review

A dose review works best when your prescriber can see what you have used, what changed and when. Bring the packaging or clear photographs, your prescription instructions and a dated symptom record. Include estrogen, progesterone or other progestogens, and testosterone if prescribed. A clear record helps your prescriber assess how treatment is working.

Record the product before the symptoms

Write down the brand, formulation, strength and units exactly as printed. Add how much you actually use, the route, application or dosing times, and the date of your last change. Record missed doses, delayed patch replacements, poor adhesion and any difference between the instructions and your routine.

For example, Climara 0.025 mg/day delivers 25 micrograms of estradiol per day, while the patch is replaced once weekly. Other patch brands may have different replacement schedules. A daily delivery rate does not mean daily replacement. [3]

Divigel uses different units: a 0.25-gram packet contains 0.25 mg estradiol. Record both the gel quantity and hormone content. That packet is not directly equivalent to a 0.025 mg/day patch or an oral tablet; absorption differs by formulation. [4]

Make symptoms comparable over time

Choose a few outcomes that prompted treatment. Note daily hot-flush counts, nights interrupted by sweating, and how bothersome symptoms feel on a consistent scale of your choosing. Mark treatment changes on the same record. An entry such as “four night sweats, awake twice” describes frequency and disruption together. The scale is a communication aid, not a validated dosing tool.

Symptom outcomes matter in dose-finding research. A 12-week trial in 333 menopausal women compared oral estradiol doses with placebo using daily hot-flush frequency and severity. Response differed by dose and time point. The tested oral formulation and symptom outcomes define what that trial can show. [7]

Include bleeding and the progestogen plan

If you have a uterus and use systemic estrogen, bring the endometrial-protection plan to every estrogen review. Record when progestogen was taken and whether bleeding matched the expected pattern. Cyclic treatment may produce scheduled withdrawal bleeding; continuous treatment has a different pattern. The appropriate progestogen regimen depends partly on estrogen exposure. [6]

In the PEPI trial, combined estrogen–progestogen regimens had endometrial hyperplasia rates similar to placebo, unlike estrogen alone. This supports reviewing protection alongside estrogen changes. [8] PROMETRIUM’s US labeled regimen is specific to its studied setting; it does not establish one progesterone schedule for every patch strength. Drowsiness or dizziness also belongs in your record. [5]

Report unexpected bleeding, particularly heavy or prolonged bleeding, rather than waiting for a routine appointment. Assessment considers timing, regimen, adherence and individual risk. [11]

Know what the review can answer

NICE, the UK guideline body, recommends review at three months for efficacy and tolerability, then annually, with earlier review when clinically indicated.[2] Routine follow-up usually starts with treatment response and the clinical question. NAMS advises that serum hormone testing is rarely needed and that saliva or urine tests are unreliable for dose adjustment.[1]

Testosterone has separate monitoring requirements when prescribed for appropriately assessed hypoactive sexual desire disorder. Bring baseline total testosterone and SHBG results, prescribed follow-up tests and side-effect notes. Monitoring helps avoid excessive exposure; a low number alone does not diagnose the condition. [9]

List new medicines, supplements and medical diagnoses with their dates. Changes in cardiovascular or breast-cancer risk and treatment preferences may affect the review. [12] Premature ovarian insufficiency has distinct replacement and long-term health considerations, so a general menopause symptom record cannot determine its treatment plan. [10]

Frequently asked questions

›What is the starting dose for an estradiol patch?

It depends on the product and indication. Climara’s US label starts treatment for menopausal vasomotor symptoms at 0.025 mg/day, applied once weekly, with adjustment according to clinical response. Other brands have their own instructions. This is not a universal starting dose for every situation. [3]

›How long does HRT titration take?

There is no fixed duration for every product or person. NICE recommends an initial review at three months, then annually, with earlier review for clinical concerns. Persistent ineffective treatment, troublesome side effects or unexpected bleeding can justify contacting your prescriber sooner. [2][11]

›What serum estradiol level should I target on HRT?

There is no universal serum estradiol target for routine menopausal HRT. Symptoms, tolerability and individual clinical factors usually guide review; serum testing is rarely needed. Premature ovarian insufficiency requires a distinct treatment plan rather than a target borrowed from general menopause advice. [1][10]

›How do I know if my estradiol dose is too low?

Persistent symptoms deserve review of treatment response and how the product is being used. Record frequency, bothersomeness, missed doses, patch adhesion and dates of changes so your prescriber can assess the next step.[3][7]

›Can I use an estradiol patch and oral estradiol together?

Ask your prescriber before adding another estrogen product. A combined prescription needs review of the actual exposures, individual risks and endometrial-protection plan when a uterus is present. Bring both labels and instructions.[6][12]

›What is the difference between cyclic and continuous progesterone?

Cyclic, or sequential, progesterone is taken on specified days each month and usually allows a scheduled withdrawal bleed. Continuous progesterone is taken daily, generally aiming for no scheduled bleeding. Selection and adequate endometrial protection depend on your circumstances and estrogen regimen. [6]

›How much testosterone cream do women need?

There is no universal cream amount: concentration and the amount applied both matter. ISSWSH supports testosterone for appropriately assessed hypoactive sexual desire disorder, with monitoring to avoid levels above the laboratory’s physiologic premenopausal range. Recheck total testosterone 3–6 weeks after starting and within six weeks of an increase; once stable, monitor every 4–6 months. [9]

›Does oral estradiol need a different titration approach than the patch?

The routes have different absorption and dosing instructions. Record tablet strength for oral estradiol; for a patch, record its daily delivery rate, replacement frequency and adhesion. Oral trial results apply to the tested formulation.[3][7]

›Is FSH useful for monitoring HRT dose?

FSH is not a routine HRT dose-monitoring test. NICE generally recommends diagnosing menopause without laboratory tests in otherwise healthy people aged 45 or older with typical symptoms. FSH has selected diagnostic uses in younger or uncertain cases, rather than serving as a dose target. [2]

›What blood tests should I get before starting HRT?

There is no mandatory hormone-and-general-blood-test panel for everyone starting menopausal HRT. Testing depends on your history, symptoms and planned treatment. For testosterone, ISSWSH recommends baseline total testosterone, SHBG, liver function and fasting lipids. Other tests may be appropriate for individual concerns. [2][9]

›When should I consider reducing my HRT dose?

Discuss reduction when your goals change, side effects become troublesome, or new medical factors alter the benefit–risk balance. There is no automatic two-year reduction rule. Longer use can remain appropriate for a documented indication with periodic reassessment. [1][12]

›Does HRT dose need to change as I get older?

Age prompts reassessment, not an automatic dose change. Review symptoms, formulation, medical history, new medicines and preferences. NAMS does not recommend routinely stopping at age 60 or 65, but continued treatment needs an individualized benefit–risk review. [1]

References

Sources checked October 14, 2026.

1. The North American Menopause Society. The 2022 hormone therapy position statement.
2. NICE. Menopause: identification and management (NG23), recommendations.
3. DailyMed. CLIMARA prescribing information. Updated March 26, 2026.
4. DailyMed. DIVIGEL prescribing information. Updated February 27, 2026.
5. DailyMed. PROMETRIUM prescribing information. February 2026 label.
6. British Menopause Society. Progestogens and endometrial protection.
7. Notelovitz M, et al. Initial 17β-estradiol dose for treating vasomotor symptoms. 2000.
8. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. 1996.
9. Parish SJ, Simon JA, Davis SR, et al. ISSWSH clinical practice guideline for systemic testosterone for hypoactive sexual desire disorder in women. 2021.
10. Panay N, et al. Evidence-based guideline: premature ovarian insufficiency. 2024.
11. British Menopause Society. Management of unscheduled bleeding on hormone replacement therapy.
12. Endocrine Society. Treatment of symptoms of the menopause: clinical practice guideline. 2015.